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Abstract
Background: A database analysis was conducted to assess
the effectiveness of sucroferric oxyhydroxide (SO) on lowering serum phosphorus and phosphate binder (PB) pill burden among adult peritoneal dialysis (PD) patients prescribed
SO as part of routine care. Methods: Adult PD patients (n =
258) prescribed SO through a renal pharmacy service were
analyzed. Baseline was 3 months before SO prescription. SOtreated follow-up was for 6 months or until either a new PB
was prescribed, SO was not refilled, PD modality changed, or
patient was discharged. In-range serum phosphorus was defined as ≤5.5 mg/dL. Results: At baseline, mean serum phosphorus was 6.59 mg/dL with 10 prescribed PB pills/day. The
proportion of patients achieving in-range serum phosphorus increased by 72% from baseline to month 6. Prescribed
PB pills/day decreased by 57% (10 at baseline to 4.3 at SO
follow-up, p < 0.0001). The mean length of SO follow-up was
5.1 months; SO follow-up ended for 38, 27, and 50 patients
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at months 4, 5, and 6, respectively, due to no further PB fills,
and for 10, 11, and 4 patients at months 4, 5, and 6, respectively, due to another PB prescribed. In patients with baseline serum phosphorus >5.5 mg/dL who achieved in-range
serum phosphorus during SO follow-up for ≥1 quarter, a notable improvement in serum phosphorus (6.54 to 5.10 mg/
dL, p < 0.0001) was observed, and there was a 53% reduction
in PB pill burden (9.9 to 4.7, p < 0.0001). Conclusion: Among
PD patients prescribed SO as part of routine care, improvements in serum phosphorus control and >50% reduction in
PB pills/day were observed.
© 2018 The Author(s)
Published by S. Karger AG, Basel

Background

Peritoneal dialysis (PD) represents a safe and cost-effective treatment modality for patients with end-stage renal disease (ESRD) [1–4]. In the United States, by the end
of 2014, 6.9% of prevalent ESRD cases were treated with
PD [5]. Disorders of phosphorus metabolism among
ESRD patients are common, with serum phosphorus levels in PD patients generally lower than in hemodialysis
Kamyar Kalantar-Zadeh, MD, PhD
University of California Irvine School of Medicine
1001 Health Sciences Road
Irvine, CA 92697-3950 (USA)
E-Mail kkz @ uci.edu

(HD) patients [6–8], though treatment with oral phosphate binders (PBs) are usually indicated [9]. Favorable
properties of PBs would include low pill burden, low cost,
minimal systemic absorption, and minimal side effects [6,
10]. Potential risks include toxicity, gastrointestinal side
effects, and contribution to hypercalcemia [11–13]. Adherence to PB therapy is essential for phosphorus control,
and low pill burden may be a key factor in adherence [14–
16]. PD patients are prescribed, on average, 16–19 pills/
day [17, 18] and half are PBs [18].
Sucroferric oxyhydroxide (SO) is an iron-based, chewable PB with a low pill burden indicated for treatment of
hyperphosphatemia in patients with chronic kidney disease on dialysis. Coyne et al. [19] reported significantly
decreased pill burden and improved serum phosphorus
levels among HD patients prescribed SO as part of routine clinical care. Floege et al. [20] reported results from
a phase 3 randomized controlled trial and found SO to be
non-inferior to sevelamer carbonate for the control of serum phosphorus in PD patients, with a lower pill burden.
The objective of this retrospective database analysis was
to assess the effectiveness of SO on lowering serum phosphorus levels and PB pill burden among adult PD patients
prescribed SO as part of routine clinical care.

Methods
SO (Velphoro®, Fresenius Medical Care Renal Therapies
Group, Waltham, MA, USA) is usually prescribed with a starting
dose of 3 pills/day, administered as 1 tablet with each meal and titrated in increments or decrements of 1 tablet per day.
Adult (age >18 years) PD patients who were prescribed SO as
part of routine clinical care at Fresenius Kidney Care (FKC) facilities and who received their first SO prescription through FreseniusRx (a specialty renal pharmacy service) between April 1, 2014
and October 30, 2015, were included in this retrospective analysis.
Patients were required to have ≥3 months of SO prescription fills
recorded, uninterrupted by another PB. De-identified demographic and clinical data were retrieved from the FKC data warehouse; PB prescription information originated from the FreseniusRx database. To supplement baseline PB information, we used PB
orders from the FKC Electronic Health Record (EHR). However,
we cannot assume that the orders recorded in this database are as
precise or accurate as documented prescription fills; thus, only
documented prescriptions were used for calculations of PB pills
per day. Treatment periods for assessment and comparison were
defined as baseline (BL; 3 months before SO prescription), and SOtreated follow-up (SO; up to 6 months of SO prescription). SOtreated follow-up was 6 months or until either a new PB was prescribed, SO was not refilled, PD modality changed, or patient was
discharged from FKC.
Basic demographic and treatment characteristics were evaluated at baseline. Clinical parameters included PB pills/day, min-
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eral and bone disease markers (serum phosphorus, serum calcium,
intact parathyroid hormone [iPTH]), nutritional and clearance
parameters (weight, serum albumin, normalized protein catabolic
rate [nPCR], serum creatinine, total Kt/V [PD + residual renal
function], PD Kt/V, and residual urea clearance [Kru]); and anemia
and iron indices (ferritin, transferrin saturation [TSAT], hemoglobin, and iron). Laboratory tests were measured monthly, except for
ferritin and iPTH, which were measured quarterly. Calcium was
albumin-corrected using the Payne’s formula [21]. Serum albumin
and nPCR were each divided by serum phosphorus to calculate
phosphorus-attuned albumin and nPCR. Baseline Kru was categorized into 3 groups: unavailable; ≤3 mL/min/1.73 m2; and >3.0 mL/
min/1.73 m2. Spectra Laboratories (Rockleigh, NJ, USA) performed all laboratory tests.
Repeated-measures data were analyzed using linear mixed-effects regression. Mean clinical measures were summarized using
least-squared means and compared between baseline and SO follow-up. In-range serum phosphorus was defined as mean serum
phosphorus ≤5.5 mg/dL. To determine the impact of intermittent
HD on changes in serum phosphorus, an analysis was conducted
where all serum phosphorus levels were deleted for months when
patients had intermittent HD (n = 23). A sub-group analysis was
conducted for all patients achieving serum phosphorus ≤5.5 mg/
dL during at least 1 quarter of SO follow-up and a subset of these
patients with baseline serum phosphorus >5.5 mg/dL. Sub-analysis by Kru group was conducted to assess effect measure modification by residual renal function. For this sub-analysis, missing baseline Kru were imputed for 33 patients with follow-up Kru measured.
Serum phosphorus levels were compared for subgroups that did
and did not complete 6 months of SO treatment. P values <0.05
were considered statistically significant. All analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
This database analysis was approved by the New England Institutional Review Board.

Results

Analysis of Study Cohort (n = 258)
In total, 258 patients met the requirements for analysis. Patients were, on average, 50.6 ± 13.9 years old, with
a mean dialysis vintage of 29.3 ± 27.6 months (Table 1).
The majority of patients (76%) received continuous cycling PD (CCPD), 13.2% received continuous ambulatory PD (CAPD), and the remaining patients (10.8%)
switched from CAPD to CCPD during baseline. On average, patients were prescribed 4.9 ± 1 exchanges per day
and 6.8 ± 0.6 days per week. The mean length of SO follow-up was 5.1 months; 151 patients did not complete all
6 months of SO monotherapy. SO follow-up ended for 38,
27, and 50 patients at months 4, 5, and 6, respectively, due
to no further PB fills, and for 10, 11, and 4 patients at
months 4, 5, and 6, respectively, due to another PB prescribed. The other 11 patients who did not complete the
6 months were discharged from the clinic or switched to
Kalantar-Zadeh et al.

HD. (See monthly patient disposition in online suppl. Table S1; for all online suppl. material, see www.karger.com/
doi/10.1159/000487856). The majority of patients with
PB fills from FreseniusRx at baseline (n = 92) were prescribed sevelamer (63.0%), followed by calcium acetate
(20.7%), more than 1 PB (10.9%) and lanthanum carbonate (5.4%). The remainder of patients (n = 166) had no
recorded baseline PB fills in the FreseniusRx database.
Among the 166 patients who did not receive a FreseniusRx PB fill during baseline, 110 patients had PB prescriptions available through the FKC EHR database. Figure 1
shows that the distribution of PB type was similar at baseline for patients with and without PB prescriptions
through FreseniusRx.
Mean changes between baseline and SO follow-up are
compared in Table 2. A significant improvement was observed in mean serum phosphorus (6.59 mg/dL at BL to
6.26 mg/dL at SO, p < 0.0001). Prescribed PB pills/day
decreased by 57% from 10 pills/day at baseline to 4.3 pills/
day at SO follow-up (p < 0.0001). There was a slight decrease in corrected calcium (9.36 to 9.31 mg/dL, p = 0.018)
and a slight increase in intact PTH from 468 to 497 pg/
mL (p = 0.03). There were no changes observed in unadjusted nPCR (1.0 g/kg/day at BL and SO, p = 0.9) and
weight (86.8 to 86.9 kg, p = 0.8), but a slight decrease was
observed in unadjusted serum albumin from 3.70 to 3.62
g/dL (p < 0.0001). When adjusted for serum phosphorus,
increases were observed in phosphorus-attuned albumin
from 0.6 × 103 at BL to 0.63 × 103 at SO follow-up (p <
0.0001), and phosphorus-attuned nPCR (0.17 × 103 to
0.18 ×103 dL/kg/day, p = 0.04). Although there was a
slight decrease in Kru (2.85 to 2.47 mL/min/1.73 m2, p =
0.008) and increase in serum creatinine (12.0 to 12.2 mg/
dL, p = 0.001), there were no changes in total Kt/V (2.1 at
BL and SO, p = 0.7) and a numeric increase in PD Kt/V
(1.65 to 1.70, p = 0.5).
As a sensitivity analysis, several subgroup analyses on
serum phosphorus changes were conducted. There were
21 patients who received intermittent HD during the
study periods. Changes in serum phosphorus levels after
removing these measurements showed a similar improvement in serum phosphorus (6.60 to 6.25 mg/dL, p <
0.0001). Patients who completed the full 6 months of SO
follow-up (n = 107) had serum phosphorus reduced from
6.56 mg/dL at BL to 6.16 mg/dL at SO follow-up (p <
0.0001). PB pill burden reduced from 9.9 to 4.3 pills/day
(p < 0.0001) for the patients prescribed PB at baseline (92
patients out of the 107). Patients with PB prescriptions
recorded through FreseniusRx at baseline and who completed the 6-month follow-up (n = 30) had a mean serum

Table 1. Baseline characteristics at SO therapy initiation
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Baseline characteristic

Study cohort
(n = 258)

Age, years
50.6±13.9
Dialysis vintage, months
29.3±27.5
BMI, kg/m2
30.4±8
Gender, male, n (%)
143 (55.4)
Race, n (%)
White
160 (62.0)
African American
64 (24.8)
Other
34 (13.2)
Diabetes, n (%)
121 (46.9)
Primary cause of ESRD, n (%)
Diabetes mellitus
90 (34.9)
Hypertension
69 (26.7)
Glomerulonephritis
47 (18.2)
Polycystic kidney disease
10 (3.9)
Other
34 (13.2)
Unknown
8 (3.1)
Baseline PB dispensed through FreseniusRx
No PB recorded, n (%)
166 (64.3)
PB recorded in the FKC EHR database, n (%) 110 (66.3)
PB recorded, n (%)
92 (35.7)
Calcium acetate, n (%)
19 (20.7)
Lanthanum carbonate, n (%)
5 (5.4)
Sevelamer, n (%)
58 (63.0)
>1 PB recorded, n (%)
10 (10.8)
PD modality, n (%)
Manual (CAPD)
34 (13.2)
Automated (CCPD)
196 (76)
Switched (CAPD to CCPD)
28 (10.8)
Clinical parameters
Serum phosphorus, mg/dL
6.5±1.4
Albumin-corrected calcium, mg/dL
9.4±0.7
Intact PTH, pg/mL
459±317
Serum albumin, g/dL
3.7±0.4
Kru, mL/min/1.73 m2
2.72±2.45
PD Kt/V
1.7±0.4
Total Kt/V
2.2±0.5
Values are expressed as mean ± SD, or n (%).
BMI, body mass index (kg/m2); CAPD, continuous ambulatory
PD; CCPD, continuous cycling PD; Kru, residual urea clearance;
FKC EHR, Fresenius Kidney Care Electronic Health Records; PB,
phosphate binder; PD, peritoneal dialysis; PTH, parathyroid hormone; ESRD, end-stage renal disease.

phosphorus decrease from 6.33 mg/dL at baseline month
–1 (month before switch to SO) to 5.37 mg/dL at month
6 of SO follow-up (p < 0.001) and percentage of patients
achieving in-range serum phosphorus levels increased
from 11 (29.7%) patients at baseline month –1 to 18
(48.6%) patients at SO follow-up month 6. Patients with
PB prescriptions recorded through FreseniusRx or FKC
155

Study cohort (n = 258)

Patients with PB
records available
through FreseniusRx

Patients without PB
records available
through FreseniusRx

(n = 92)

(n = 166)

Sevelamer
n = 58 (63%)
Calcium acetate
n = 19 (21%)
Lanthanum carbonate
n = 5 (5%)
>1 PB*
n = 10 (11%)

Fig. 1. Baseline PB prescriptions prior to

SO initiation. * Combination of sevelamer,
calcium acetate, and/or lanthanum carbonate. FKC EHR, Fresenius Kidney Care
Electronic Heath Record database; PB,
phosphate binder.

EHR database at baseline and who completed the 6-month
follow-up (n = 84) had a mean serum phosphorus decrease from 6.90 mg/dL at baseline month –1 to 5.94 mg/
dL at SO follow-up month 6 (p < 0.0001) and the percentage of patients achieving in-range serum phosphorus levels increased from 21 (25%) patients at baseline month –1
to 34 (40.5%) at SO follow-up month 6. An additional
analysis of patients who did not complete the full 6 months
of SO follow-up was conducted using all serum phosphorus measurements available, regardless of the end of SO
monotherapy prescription, and they had a mean serum
phosphorus of 6.62 at BL and 6.34 mg/dL at follow-up
(p < 0.001).
At baseline, 127 (49.2%) patients received IV iron therapy and 195 (75.6%) patients received erythropoietinstimulating agent therapy. At SO follow-up, 132 (51.1%)
patients received IV iron therapy (iron sucrose) and 200
(77.5%) patients received erythropoietin-stimulating
agent therapy. Mean iron sucrose dose was minimally
changed from 202 mg/month at BL to 204 mg/month at
SO follow-up (p = 0.6). Similarly, mean epoetin alfa dose
was minimally changed from 11,805 to 11,667 units/
month (p = 0.5) among patients treated exclusively with
epoetin alfa (83%). Among patients who received IV iron
therapy (n = 165), significant increases in ferritin (748 to
940 ng/mL, p < 0.0001), TSAT (34.0 to 38.4%, p < 0.0001)
156
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Patients without PB
records available
through FKC EHR database

Patients with PB
records available
through FKC EHR database

(n = 56)

(n = 110)
Sevelamer
n = 65 (59%)
Calcium acetate
n = 22 (20%)
Lanthanum carbonate
n = 8 (7%)
>1 PB*
n = 15 (14%)

and hemoglobin (10.6 to 10.7 g/dL, p = 0.08) were observed from baseline to SO follow-up. Among patients
who did not receive any IV iron therapy (n = 93), serum
ferritin increased from 801 to 876 ng/mL (p = 0.02), hemoglobin increased from 11.2 to 11.3 g/dL (p = 0.03) and
TSAT was unchanged (38.5%, p = 0.9).
The percentage of patients achieving in-range serum
phosphorus (≤5.5 mg/dL) increased from baseline to SO
follow-up (Fig. 2). At baseline 30.1, 25.4, and 25.8% of
patients were in-range for serum phosphorus at months
–3, –2, and –1 respectively. During SO follow-up, the percent of patients who were in-range for serum phosphorus
increased to 35.3, 37.5, 41.8, 36.8, 38.9, and 44.4% at
months 1–6, respectively. Comparing BL month –1 to SO
follow-up month 6, there was a 72% increase in patients
achieving in-range serum phosphorus along with >50%
reduction in PB pills/day.
Analysis of Patients with In-Range Serum Phosphorus
Recorded During SO Follow-Up
Patients (n = 110) who achieved in-range serum phosphorus during ≥1 quarter of SO follow-up were analyzed
to determine the associated effects of being in-range on
other mineral bone disease and nutrition markers (Table
3). Among these patients, 75 patients (68%) had a recorded PB at baseline (67% sevelamer, 27% calcium acetate,
Kalantar-Zadeh et al.

Table 2. Comparison of clinical parameters between baseline and SO therapy (258 PD patients)

Baseline

PB pills/day*
Mineral and bone disease markers
Serum phosphorus, mg/dL
Albumin-corrected calcium, mg/dL
Intact PTH, pg/mL
Nutritional and clearance parameters
Weight, kg
Serum albumin, g/dL
Phosphorus-attuned albumin, ×103
nPCR, g/kg/day
Phosphorus-attuned nPCR, ×103 dL/kg/day
Serum creatinine, mg/dL
Kru, mL/min/1.73 m2
PD Kt/V
Total Kt/V

10.0 (0.2)

4.3 (0.2)

<0.0001

6.59 (0.09)
9.36 (0.04)
468 (23)

6.26 (0.09)
9.31 (0.04)
497 (22)

<0.0001
0.018
0.032

86.8 (1.5)
3.70 (0.02)
0.6 (0.01)
1.0 (0.03)
0.17 (0.005)
12.0 (0.3)
2.85 (0.20)
1.65 (0.05)
2.1 (0.06)

86.9 (1.5)
3.62 (0.02)
0.63 (0.01)
1.0 (0.02)
0.18 (0.004)
12.2 (0.3)
2.47 (0.19)
1.70 (0.04)
2.1 (0.05)

0.8
<0.0001
<0.0001
0.9
0.044
0.001
0.008
0.5
0.7

801 (66)
38.5 (1.4)
11.2 (0.2)
98.1 (3.5)

876 (65)
38.5 (1.3)
11.3 (0.2)
93.2 (3.2)

0.018
0.9
0.039
0.077

748 (36)
34.0 (0.9)
10.6 (0.1)
85.8 (2.4)

940 (34)
38.4 (0.8)
10.7 (0.1)
92.3 (2.1)

<0.0001
<0.0001
0.078
0.005

Anemia and iron indices
Patients not receiving IV iron therapy (n = 93)
Ferritin, ng/mL
Transferrin saturation, n (%)
Hemoglobin, g/dL
Iron, mcg/dL
Patients receiving IV iron therapy (n = 165)
Ferritin, ng/mL
Transferrin saturation, n (%)
Hemoglobin, g/dL
Iron, mcg/dL

SO follow-up

p value

Parameter

Values are expressed as least-squared means (SE), p values compare least-squared means between treatment
periods.
* Pill burden at baseline was calculated only for patients who received PB prescriptions through FreseniusRx
(n = 92). Follow-up PB pill burden for patients with no baseline binder available through FreseniusRx (n = 166)
was found to be 4.3 SO pills/day.
Kru, residual urea clearance; nPCR, normalized protein catabolic rate; PD, peritoneal dialysis; PTH, parathyroid hormone; SO, sucroferric oxyhydroxide; PB, phosphate binder.

4% lanthanum carbonate, and 3% PB combination therapy), and 35 patients (32%) did not have a recorded PB at
baseline (for prescriptions by month, see online suppl.
Table S2). Comparing baseline and SO follow-up, a >50%
reduction in PB pill burden (9.3 to 4.4 pills/day, p < 0.0001)
and an improvement in serum phosphorus (5.81 to 4.97
mg/dL, p < 0.0001) were observed. Intact PTH was unchanged (406 to 425 pg/mL, p = 0.4). There was a slight
decrease in corrected calcium (9.43 to 9.36 mg/dL, p =
0.08) and serum albumin (3.70 to 3.64 g/dL, p < 0.001),
and no changes observed in nPCR (1.0 g/kg/day, p = 0.2).
Comparing baseline and SO follow-up, there were significant improvements in phosphorus-attuned albumin
(0.68 × 103 to 0.77 × 103, p < 0.0001) and phosphorus-attuned nPCR (0.18 × 103 to 0.21 × 103 dL/kg/day, p < 0.001).

Among patients who achieved in-range serum phosphorus during SO follow-up, 97 patients did not change
PD prescription modality (86% CCPD, 14% CAPD,
mean serum phosphorus 5.69 mg/dL at baseline and 4.94
mg/dL at SO follow-up, p < 0.0001), and 13 patients were
prescribed a switch between both PD modalities (mean
serum phosphorus was 6.42 mg/dL at baseline and 4.92
mg/dL at SO follow-up, p < 0.001). Fifty-nine patients
did not change the prescribed number of PD exchanges/
day (mean number of PD exchanges = 4.7/day, mean serum phosphorus 5.57 mg/dL at baseline and 5.02 mg/dL
at SO follow-up, p < 0.0001). Fifty-one patients had an
increase in prescribed number of PD exchanges/day
(mean = 4.8/day at baseline and 5.2/day at follow-up)
and had a mean serum phosphorus of 6.03 mg/dL at
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PB pills/day

Patients with serum phosphorus ≤5.5 mg/dL, %

9.9
50

10.0

9.8

3.9

4.1

4.2

Baseline

4.4

4.7

4.9

SO

40

30

20

10

Discussion
0

–3

–2

–1

1

2

–3

3

4

5

6

+6
Time, months

Fig. 2. Percent of patients with monthly serum phosphorus ≤ 5.5

mg/dL at baseline and SO follow-up. PB pills/day for patients with
in-range serum phosphorus decreased from (9.7, 8.8, and 9.0) at
baseline to (3.9, 4.4, 4.2, 4.4, 4.5, and 4.8) at SO follow-up. SO, sucroferric oxyhydroxide; PB, phosphate binder.

baseline and 4.83 mg/dL at SO follow-up (p < 0.0001).
Eighty-three patients received 7 days/week of PD treatment throughout baseline and follow-up (mean serum
phosphorus = 5.81mg/dL at baseline and 4.91 mg/dL at
SO follow-up, p < 0.0001), and 27 patients had an increase in prescribed number of days of PD treatment (5.6
PD treatment days/week at baseline and 6.8 PD treatment days/week at SO follow-up) and serum phosphorus
decrease of 0.7 mg/dL (5.69 mg/dL at baseline to 4.98
mg/dL at SO follow-up, p = 0.008). A subset of the patients (n = 63) who achieved in-range serum phosphorus
during SO follow-up had serum phosphorus levels >5.5
mg/dL during baseline (Table 3). Comparing baseline
and SO follow-up, a notable improvement in serum
phosphorus (6.54 to 5.10 mg/dL, p < 0.0001) was observed along with a 53% reduction in PB pill burden (9.9
to 4.7 pills/day, p < 0.0001). There were nonsignificant
changes in intact PTH (430 to 391 pg/mL, p = 0.09), corrected calcium (9.31 to 9.36 mg/dL, p = 0.3), and total
Kt/V (2.0 to 2.2, p = 0.3). Although a slight decrease in
serum albumin (3.71 to 3.63 g/dL, p = 0.001) was observed, phosphorus-attuned albumin (0.59 × 103 to
0.75 × 103, p < 0.0001) and phosphorus-attuned nPCR
(0.17 × 103 to 0.21 × 103 dL/kg/day, p < 0.0001) increased.
158

Assessing the Impact of Residual Renal Function on
PB Pill Burden and Serum Phosphorus Levels
In Table 4, patients are stratified by their baseline Kru.
The Kru >3 group had more patients with baseline and SO
follow-up serum phosphorus levels ≤5.5 mg/dL (40.2 and
52.8%, respectively) when compared to patients for whom
Kru was not measured (15.6 and 31.3%) and patients with
Kru ≤ 3 (14.8 and 25.4%). Patients with Kru >3 also had
lower baseline and SO follow-up PB pills/day (6.7 and 3.7
pills, respectively) when compared to patients for whom
Kru was not measured (10.7 and 4.4 pills) and patients
with Kru ≤3 (10.6 and 4.4 pills).
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The current retrospective analysis included patients
treated under routine care and the analysis had no impact
on the prescription or treatment of the patients. The patients did not go through a wash-out period and the current
analysis relied on physician judgment and preference in PB
choice. Compared to a representative national sample of
dialysis patients, with 34% of patients with serum phosphorus >5.5 mg/dL [22], the patients in our analysis could be
considered difficult to treat, as 74% had serum phosphorus
>5.5 mg/dL. However, a 72% increase of patients in-range
for serum phosphorus (≤5.5 mg/dL) was achieved with SO,
with an absolute level of 44.4% of patients in-range at
6 months and a 57% reduction in PB pills/day.
Nonadherence to prescribed PB regimen has been reported in 62% of dialysis patients [18]. PB pill burden is a
cited determinant of PB adherence [6]. Thus, the observed average pill burden decreased from 10 to 5 pills/
day is favorable. The increase in adherence to PB therapy
may be a factor in the improvements in serum phosphorus control in patients prescribed SO.
Floege et al. [20], as a sub-analysis of a phase III study,
focused on PD patients over 1 year of follow-up and
found SO effective for the lowering of serum phosphorus
levels. Although patients in the SO arm had higher baseline serum phosphorus levels when compared to the
sevelamer arm (7.5 mg/dL compared to 6.7 mg/dL), there
were similar proportion of patients who achieved withinrange serum phosphorus at 24 and 52 weeks in the SO
(57.1 and 62.5%) and sevelamer (60.7 and 64.3%) arms.
This was accomplished with 58% lower pill burden when
using SO compared to sevelamer, which is comparable to
the findings of our analysis.
In this analysis, we also used 2 novel metrics to account for the role of nutritional status in the manageKalantar-Zadeh et al.

Table 3. Comparison of clinical parameters for patients with in-range phosphorus during SO follow-up

Parameter

Baseline

Patients with serum phosphorus ≤5.5 mg/dL for ≥3 months of SO follow-up (n = 110)
9.3 (0.2)
PB pills/day*
Serum phosphorus, mg/dL
5.81 (0.08)
Albumin-corrected calcium, mg/dL
9.43 (0.06)
Intact PTH, pg/mL
406 (33)
Weight, kg
88.1 (2.3)
Serum albumin, g/dL
3.70 (0.03)
Phosphorus-attuned albumin, ×103
0.68 (0.01)
Phosphorus-attuned nPCR, ×103 dL/kg/day
0.18 (0.01)
Serum creatinine, mg/dL
10.3 (0.4)
Kru, mL/min/1.73 m2
3.58 (0.38)
PD Kt/V
1.57 (0.12)
Total Kt/V
2.2 (0.1)
Subset of patients with serum phosphorus >5.5 mg/dL at baseline (n = 63)
9.9 (0.3)
PB pills/day**
Serum phosphorus, mg/dL
6.54 (0.10)
Albumin-corrected calcium, mg/dL
9.31 (0.09)
Intact PTH, pg/mL
430 (32)
Weight, kg
85.9 (2.7)
Serum albumin, g/dL
3.71 (0.04)
Phosphorus-attuned albumin, ×103
0.59 (0.01)
Phosphorus-attuned nPCR, ×103 dL/kg/day
0.17 (0.01)
Serum creatinine, mg/dL
11.7 (0.5)
Kru, mL/min/1.73 m2
2.71 (0.44)
PD Kt/V
1.59 (0.17)
Total Kt/V
2.0 (0.2)

SO follow-up

p value

4.4 (0.2)
4.97 (0.07)
9.36 (0.06)
425 (32)
87.5 (2.3)
3.64 (0.03)
0.77 (0.01)
0.21 (0.01)
10.2 (0.4)
3.25 (0.34)
1.73 (0.09)
2.3 (0.1)

<0.0001
<0.0001
0.08
0.4
0.3
<0.001
<0.0001
<0.001
0.12
0.3
0.3
0.3

4.7 (0.3)
5.10 (0.08)
9.36 (0.08)
391 (30)
87.1 (2.7)
3.63 (0.04)
0.75 (0.01)
0.21 (0.01)
11.3 (0.5)
2.40 (0.37)
1.80 (0.13)
2.2 (0.1)

<0.0001
<0.0001
0.3
0.087
0.007
0.001
<0.0001
<0.0001
0.002
0.5
0.3
0.3

Values are expressed as least-squared means (SE), p values compare least-squared means between treatment periods.
* Pill burden at baseline was calculated only for patients who received PB prescriptions through FreseniusRx (n = 68). Follow-up
PB pill burden for patients with no baseline binder available through FreseniusRx (n = 42) was found to be 4.1 SO pills/day.
** Pill burden at baseline was calculated only for patients who received PB prescriptions through FreseniusRx (n = 29). Follow-up
PB pill burden for patients with no baseline binder available through FreseniusRx (n = 34) was found to be 4.4 SO pills/day.
Kru, residual urea clearance; nPCR, normalized protein catabolic rate; PD, peritoneal dialysis; PTH, parathyroid hormone; SO, sucroferric oxyhydroxide; PB, phosphate binder.

Table 4. Comparison of pill burden and serum phosphorus by Kru at baseline
Parameter

Kru ≤3 mL/min/1.73 m2 (n = 122)

No Kru recorded (n = 64)
BL

SO

p value

BL

p value

SO

Kru >3 mL/min/1.73 m2 (n = 72)
BL

SO

p value

PB pills/day*

10.7 (0.3)

4.4 (0.3)

<0.0001

10.6 (0.3)

4.4 (0.3)

<0.0001

6.7 (0.3)

3.7 (0.3)

<0.0001

Serum phosphorus, mg/dL

6.57 (0.16)

6.21 (0.15)

0.001

6.96 (0.14)

6.52 (0.13)

<0.0001

5.97 (0.16)

5.85 (0.15)

0.22

10/64 (15.6)

20/64 (31.3)

0.008

18/122 (14.8)

31/122 (25.4)

Patients with serum
phosphorus ≤5.5 mg/dL

0.012

29/72 (40.2) 38/72 (52.8)

0.049

Values are expressed as least-squared means (SE) for continuous variables, and n/n (%) for categorical variables.
p values compare summary estimates between treatment periods.
* PB pill burden was calculated only for patients who received PB prescriptions through FreseniusRx.
BL, baseline; SO, sucroferric oxyhydroxide follow-up; Kru, residual urea clearance; PB, phosphate binder.
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ment of phosphorus, that is, phosphorus-attuned albumin and nPCR, in that serum albumin and nPCR were
each divided by serum phosphorus respectively. These
2 metrics are meant to address the concern that lowering serum phosphorus by restricting dietary protein
intake (represented by nPCR) may cause more harm
[23, 24], and that lower protein intake is associated
with lower serum albumin in dialysis patients [25]. Indeed, both low nPCR and low serum albumin levels are
associated with worse outcomes including higher mortality in dialysis patients. Hence, controlling serum
phosphorus without restricting dietary protein intake
or without lowering serum albumin is the preferred
goal.
Patients with serum phosphorus ≤5.5 mg/dL during
SO follow-up had a mean reduction in serum phosphorus
from 5.81 to 4.97 mg/dL (p < 0.0001) and a 54% reduction
in PB pills/day. Significant improvements in phosphorusattuned albumin (0.68 × 103 to 0.77 × 103, p < 0.0001) and
phosphorus-attuned nPCR (0.18 × 103 to 0.21 × 103 dL/
kg/day, p < 0.001) were also observed. In patients who
achieved in-range serum phosphorus during SO followup but had serum phosphorus levels >5.5 mg/dL during
baseline, a notable improvement in serum phosphorus
(6.54 to 5.1 mg/dL, p < 0.0001) and iPTH (430 to 391 pg/
mL, p = 0.09) were observed, along with a 53% reduction
in PB pills/day (9.7 to 4.6, p < 0.0001) Treatment with calcimimetics and active vitamin D for all patients and patients with in-range serum phosphorus is shown in online
supplementary Tables S3, S4. Phosphorus-attuned albumin (0.59 × 103 to 0.75 103, p < 0.0001) and phosphorusattuned nPCR (0.17 × 103 to 0.21 × 103 dL/kg/day, p <
0.0001) also increased from baseline. These changes may
show the benefits of achieving in-range serum phosphorus levels.
Residual renal function is a contributor to phosphate
clearance in PD patients [26]; thus, we stratified patients
based on Kru at baseline. Patients with Kru >3 had a higher
percentage with in-range serum phosphorus levels at
baseline and SO follow-up when compared to patients
without baseline Kru measured or Kru ≤3. There was also
a lower number of PB pills/day in the patients with Kru >3
at both baseline (6.7) and SO follow-up (3.7) compared to
baseline (10.7 and 10.6) and SO follow-up (4.4 and 4.4) for
patients without recorded Kru and Kru ≤3, respectively.
SO is an iron-based PB thus anemia and iron indices
were analyzed. The changes in ferritin and TSAT levels
were consistent with those mentioned in prior reports of
minimal iron absorption in phase III clinical trial results
[20, 27]. Patients not treated with IV iron during the
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phase III clinical trial showed small mean increase in serum ferritin (+71.9) and TSAT (+3.9%) between weeks 24
and 52 [27].
Limitations of our study include utilization of existing clinical records. Although the results may be more
generalizable, possible errors or missing data from the
clinical database are possible. Our analysis relies on
pharmacy fills, which allows for good accuracy for timing and pills/day. However, follow-up ends when patient switches their pharmacy, even if medication is not
discontinued. Reasons for patient being switched from
their baseline PB to SO or discontinuing SO during follow-up are not available but may include non-adherence to filling prescriptions, adverse events, switch to
another pharmacy, insurance coverage, and out of
pocket costs. Although dietitians provide nutritional
education to patients using approved educational materials, exact dietetic advice was not sufficiently recorded in the EHR. Reasons for discontinuation of baseline
or follow-up PBs were not available. Also, there is no
independent unexposed group available for comparison with the SO group, and so the SO group acts as
their own comparator group during baseline.
Conclusion

In conclusion, the number of prescribed PB pills/day
was reduced by half among adult PD patients treated with
SO, while the proportion of patients who achieved inrange serum phosphorus (serum phosphorus ≤5.5 mg/
dL) increased.
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